1. Progression-free survival was significantly greater in the durvalumab plus bevacizumab group compared to placebo. 2. Common treatment-related adverse events...

1. Composite of coronary heart disease death and non-fatal myocardial infarction was less frequent in the CCTA group compared to...

1. Progression-free survival was significantly greater in the lenvatinib plus pembrolizumab group compared to placebo. 2. Overall survival was higher...

1. Treatment failure was greater in the antibiotic group compared to appendicectomy group. 2. Significantly more patients in the antibiotic...

1. Patients in the endovascular therapy group achieved greater functional outcomes at 90 days. 2. Endovascular therapy resulted in significantly...

1. CDASI-A score at 12 weeks was significantly lower in dazukibart 600 mg versus placebo, suggesting reduced morbidity. 2. Treatment-related...

1. The composite of all-cause mortality, myocardial infarction, and stroke favoured FFR-guided PCI plus TAVI compared to SAVR plus CABG....

1. The composite of patient-reported clinical response and endoscopic response was significantly greater in mirikizumab versus placebo. 2. Clinical remission...

1. 89% of patients achieved transfusion independence with beti-cel gene therapy. 2. There were no serious adverse events or treatment-related...

1. Functional recovery at 90 days was lower in the balloon-guided catheter group versus the conventional catheter group. 2. All-cause...